Literature DB >> 10400860

Anaphylaxis and epinephrine auto-injector training: who will teach the teachers?

M Grouhi1, M Alshehri, D Hummel, C M Roifman.   

Abstract

BACKGROUND: Anaphylaxis is the most urgent clinical immunologic event. Effective treatment is best achieved by administration of epinephrine. Accidental exposure to the responsible allergen is the most common cause of anaphylaxis, and because it could be fatal within minutes, epinephrine in preloaded syringes and auto-injectors has been introduced. In our experience patients and medical personnel are not familiar with the use of this device.
OBJECTIVE: We sought to assess community-based professionals' knowledge of epinephrine auto-injector use and their ability to educate patients.
METHODS: Study participants consisted of a medical convention's delegates and emergency department personnel in metropolitan Toronto, as well as pharmacists of the target hospitals and retail pharmacists. Research assistants approached eligible professionals to fill out a questionnaire and demonstrate their ability to use a standard placebo auto-injector trainer.
RESULTS: A total of 122 professionals (composed of emergency physicians, family practitioners, and pediatricians) consented to participate in this study. The majority of participants (81%) did not have a placebo trainer to educate their patients; 76% did not know the 2 available dose strengths. To provide instructions and reinforcement, physicians clearly must have the necessary skills and knowledge, yet only 25% of the study participants were able to demonstrate the 3 steps of injection correctly.
CONCLUSION: Our study highlights a specific and important deficiency in medical professionals' care of patients at risk for anaphylaxis. The results challenge the current methods of educating professionals, as well as patients, when prescribing or using epinephrine auto-injectors. Clearly a new approach to educating and maintaining such skills is required.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10400860     DOI: 10.1016/s0091-6749(99)70134-x

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  9 in total

1.  Intelliject's novel epinephrine autoinjector: sharps injury prevention validation and comparable analysis with EpiPen and Twinject.

Authors:  Stephanie Guerlain; Lu Wang; Akilah Hugine
Journal:  Ann Allergy Asthma Immunol       Date:  2010-12       Impact factor: 6.347

2.  A comparison of 4 epinephrine autoinjector delivery systems: usability and patient preference.

Authors:  Stephanie Guerlain; Akilah Hugine; Lu Wang
Journal:  Ann Allergy Asthma Immunol       Date:  2010-02       Impact factor: 6.347

3.  Implementation of anaphylaxis management guidelines: a register-based study.

Authors:  Linus Grabenhenrich; Stephanie Hompes; Hannah Gough; Franziska Ruëff; Kathrin Scherer; Claudia Pföhler; Regina Treudler; Vera Mahler; Thomas Hawranek; Katja Nemat; Alice Koehli; Thomas Keil; Margitta Worm
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

4.  Demonstration of epinephrine autoinjectors (EpiPen and Anapen) by pharmacists in a randomised, simulated patient assessment: acceptable, but room for improvement.

Authors:  Sandra M Salter; Richard Loh; Frank M Sanfilippo; Rhonda M Clifford
Journal:  Allergy Asthma Clin Immunol       Date:  2014-09-19       Impact factor: 3.406

5.  Learning and Treatment of Anaphylaxis by Laypeople: A Simulation Study Using Pupilar Technology.

Authors:  Felipe Fernandez-Mendez; Nieves Maria Saez-Gallego; Roberto Barcala-Furelos; Cristian Abelairas-Gomez; Alexis Padron-Cabo; Alexandra Perez-Ferreiros; Carlos Garcia-Magan; Jose Moure-Gonzalez; Onofre Contreras-Jordan; Antonio Rodriguez-Nuñez
Journal:  Biomed Res Int       Date:  2017-07-05       Impact factor: 3.411

Review 6.  Update on the usage and safety of epinephrine auto-injectors, 2017.

Authors:  Larry S Posner; Carlos A Camargo
Journal:  Drug Healthc Patient Saf       Date:  2017-03-21

7.  Epinephrine: the drug of choice for anaphylaxis-a statement of the world allergy organization.

Authors:  Stephen F Kemp; Richard F Lockey; F Estelle R Simons
Journal:  World Allergy Organ J       Date:  2008-07       Impact factor: 4.084

Review 8.  The role of epinephrine in the treatment of anaphylaxis.

Authors:  Anne K Ellis; James H Day
Journal:  Curr Allergy Asthma Rep       Date:  2003-01       Impact factor: 4.919

9.  Pharmacists' response to anaphylaxis in the community (PRAC): a randomised, simulated patient study of pharmacist practice.

Authors:  Sandra M Salter; Brock Delfante; Sarah de Klerk; Frank M Sanfilippo; Rhonda M Clifford
Journal:  BMJ Open       Date:  2014-07-09       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.